Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 Ml3UR4VtdCCYaXHibYxqfHliQYPzZZk> MYCyMlUuOTVibl2= Mm\mO|IhcA>? MWTpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mn31NlU4QTB7MEe=
U2932  NUjwdFloS2WubDDWbYFjcWyrdImgRZN{[Xl? NGHzcXczNjVvMUWgcm0> NXm0PWRwPzJiaB?= MlOybY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXeyOVc6ODlyNx?=
OCI-LY7 NUS2TpBQS2WubDDWbYFjcWyrdImgRZN{[Xl? NHzXbFIzNjVvMUWgcm0> NFHQWGU4OiCq M1ruT4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NXHHXIxIOjV5OUC5NFc>
Farage NHn0c|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mm\lNk42NTF3IH7N NEWwTng4OiCq NFLrcHhqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MlXONlU4QTB7MEe=
LY7/EBV MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVWyMlUuOTVibl2= MkXIO|IhcA>? M2fYXYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NVm2VY5tOjV5OUC5NFc>
U2932/EBV Mn7qR4VtdCCYaXHibYxqfHliQYPzZZk> NHvsTIszNjVvMUWgcm0> NV\wTWFkPzJiaB?= M4nrXolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NVHBdYxPOjV5OUC5NFc>
HCT116 NFPxOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe1MVUxODBibl2= MnexNlQhcA>? NF74foNFVVOR M4\SSolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MnnwNlU1QTJ3MUW=
ACH-2 NF[xS|JHfW6ldHnvckBCe3OjeR?= MkfUNU06KG6P MUOyOEBp MUDpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NEHoe3czPTF2OUS2Oy=>
MCF-10A NWPJb|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7jSoFbUUN3ME2wMlE4yrFyLkCxJI5O NGHl[FAzPDl3NEi1Oi=>
MCF-7 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;CeWlEPTB;MT6xNOKyOC5{MDDuUS=> M3PRdlI1QTV2OEW2
SK-BR-3 NGCwOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjXXWVKSzVyPUGuNFDDuTBwM{Wgcm0> NEjrUokzPDl3NEi1Oi=>
MDA-MB-231 M3;qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jpWGlEPTB;MD62POKyOC5zNDDuUS=> MXOyOFk2PDh3Nh?=
PC3 NWK4XZRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJTWM2OD1zLk[1xtExNjN3IH7N MnjpNlQ6PTR6NU[=
HCT116 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTwTWM2OD1zLkCwxtExNjByIH7N MlrxNlQ6PTR6NU[=
HCT116-p21-/- NWXKN41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\DelEyUUN3ME2xMlI3yrFyLkO3JI5O NVqxZm1QOjR7NUS4OVY>
S1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuwUYVKSzVyPUeuOlfDuTBwMkmgcm0> NG[3PXQzPDl3NEi1Oi=>
SW620 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwOURCtVAvOjlibl2= NHvsOlYzPDl3NEi1Oi=>
LOX-IMVI M4Dk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwOEhCtVAvODNibl2= NHfJXFIzPDl3NEi1Oi=>
UACC-62 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPwTFNCUUN3ME2wMlU3yrFyLkG2JI5O NE[2UFAzPDl3NEi1Oi=>
MDA-MB-435 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDa[21KSzVyPUCuPVDDuTBwME[gcm0> MkjkNlQ6PTR6NU[=
SF-295 M1niOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYizTlZrUUN3ME2wMlg5yrFyLkG1JI5O Mm\uNlQ6PTR6NU[=
A549 NHLRd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVezWoh{UUN3ME2xMlI3yrFyLkK0JI5O NXzCUYtuOjR7NUS4OVY>
H460 NX\EOmdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT5RZRKSzVyPUKuOVjDuTBwOECgcm0> MV2yOFk2PDh3Nh?=
EKVX M{fXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GwOmlEPTB;MT6zN:KyOC5|NDDuUS=> NWjrZlUxOjR7NUS4OVY>
H146 NVWwSZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXCTWM2OD1yLkKyxtExNjB5IH7N NInyZpkzPDl3NEi1Oi=>
H526 NWPlVIRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP4NIZKSzVyPUCuNVXDuTBwMEOgcm0> MUCyOFk2PDh3Nh?=
HuT-78 NYjpUol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TNUGlEPTB;MT63N:KyOC52NDDuUS=> NV7kNIZDOjR7NUS4OVY>
HA NU\JVIU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PuRVAvPjJ3LUGwcm0> NVTCWWtZPDhiaB?= M{KzOIlv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NFvrW2szPDd5MUWxNC=>
MS-275 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMlYzPS1zMH7N NGHtRpQ1QCCq MlzFbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MUCyOFc4OTVzMB?=
CD4 T NXjEXFZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLUdoU1QCCq MmHCSWM2OD12LkZCtVEvOCCwTR?= NXS5elE5OjR5MkK0OVQ>
CD4 T M2i2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PLd|Q5KGh? NIPnWpdESzVyPUGwO:KyOTJ4IH7N NFL6bWMzPDd{MkS1OC=>
CD4+ T M3z1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnFR|UxRTNibl2= NGfHdnQzPDR7NUGwOS=>
A549 NVjzdHBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnOd|RYOTEkgKOxNFDDqG6P M2HHTlI1NzN4L{S4JIg> M2fYZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NIjCVmYzPDR6NUe5PS=>
JJN3 NXHITWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KzZ|I1NzR6IHi= MlrmSWM2ODxz4pEJcm08KDR64pEJbC=> NIPsT|IzPDB|MEG1NC=>
OPM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6yOE81QCCq NY[zSlRmTUN3MIO9NgKBkW6POzC0PQKBkWh? MXOyOFA{ODF3MB?=
RPMI-8226 NWD3OG5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjoW2czPC92ODDo M2nVbGVEPTC|PUGuPQKBkW6POzC0PQKBkWh? M1XrWlI1ODNyMUWw
U266 NGDhVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHUPGMzPC92ODDo MWjFR|Uxez1zMPMAjY5OQyB2OPMAjYg> MnPyNlQxOzBzNUC=
CA46 M4e1bmFxd3C2b4Ppd{BCe3OjeR?= M1PyVlYhcA>? MnK0bY5lfWOnczDicJVvfCCjcH;weI9{cXN? NXPub2tWOjN7Nk[xOlQ>
DG75 MYTBdI9xfG:|aYOgRZN{[Xl? MlrwOkBp NUnRfZdOcW6mdXPld{BvdyCjcH;weI9{cXN? NV\4dFFMOjN7Nk[xOlQ>
Ramos NXX0cnNYSXCxcITvd4l{KEG|c3H5 M1fu[|YhcA>? MXfpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= MXiyN|k3PjF4NB?=
ST486 NVz2dXhvSXCxcITvd4l{KEG|c3H5 MlfMOkBp NYCxXWNCcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NES2UHUzOzl4NkG2OC=>
HuT78 NFzjcoVCeG:ydH;zbZMhSXO|YYm= M2rs[VEwOTBxMUCwJI5O MnS4OFghcA>? M{\HNolv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= MXeyN|U{Ojd|Mh?=
DpVp35 M4HCdWFxd3C2b4Ppd{BCe3OjeR?= MoLKNU8yOC9zMECgcm0> MWG0PEBp MWjpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MlfWNlM2OzJ5M{K=
DpVp50 MlrxRZBweHSxc3nzJGF{e2G7 MUCxM|ExNzFyMDDuUS=> NEDxSWo1QCCq M2DrUIlv\HWlZYOgZox2dnRiYYDvdJRwe2m| MYqyN|U{Ojd|Mh?=
DpP75  MVvBdI9xfG:|aYOgRZN{[Xl? M{n1XlEwOTBxMUCwJI5O MYS0PEBp MX;pcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MYKyN|U{Ojd|Mh?=
SKOV-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHkVYUy6oDVMkDuUS=> M33WZlczKGh? M37Yb2ROW09? M2rDPZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MX2yN|AyODN2OB?=
Brca1 WT MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHnbZpPOeLCk{Kwcm0> NIr3Z2M4OiCq NVmwdVZUTE2VTx?= NV3EO4VDemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MnWxNlMxOTB|NEi=
Brca1 Null NETEbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOx5qCUOjCwTR?= M3m1U|czKGh? NV;ados5TE2VTx?= NYXG[5k1emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MmTmNlMxOTB|NEi=
OVCAR-8  MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD3NgKBmzJybl2= M{fL[|czKGh? MWnEUXNQ NWHLdFA{emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MWiyN|AyODN2OB?=
NCI/ADR-RES NW\P[o9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrBTHFPOeLCk{Kwcm0> MUm3NkBp MXHEUXNQ NH[wdotz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MkDSNlMxOTB|NEi=
HCT116 NGm3Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XrNVUhdk1vNUCg{txO Mn;mNlQhcA>? MWnEUXNQ NXvl[JAxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUSyNlkzPDl3OB?=
RKO NHHQ[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLpOUBvVS13MDFOwG0> M1G2blI1KGh? MlnQSG1UVw>? M37CTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MYiyNlkzPDl3OB?=
CO115 NY\Te|FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm4Z|Q4PSCwTT21NEDPxE1? NYTXRVVEOjRiaB?= M{HBW2ROW09? M2H6folvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NUfpZo1LOjJ7MkS5OVg>
HFS M1Loc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETBUoc2KG6P NUHiNmZJOjRxNEivO|IhcA>? MojrbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> Mli0NlIyODZ{OEK=
LNCaP M{f0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\uOUBvVQ>? NUewTm4zOjRxNEivO|IhcA>? NHzENVRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MYSyNlExPjJ6Mh?=
A549 M1jOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPMOUBvVQ>? M{PSV|I1NzR6L{eyJIg> NHHxdmhqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MXiyNlExPjJ6Mh?=
697  NH\MeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLLTWM2OOLCiU5ihKkzNjYEoH7N NGnNXW0zOTV|OEKxOi=>
697-R M3PxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;5SGlEPTEkgJm95qCKQC54wrDuUeKh Mn\BNlE2Ozh{MU[=
HUT78 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPXOlVwUUN3ME2xJI5O NGDKVpIzOTF7OEW0OS=>
THJ-16T NXjTeJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\YS|Ehdk1? NGi3TI0zPCCq MWHpcohq[mm2czDj[YxtKGe{b4f0bC=> MV2yNFgyODV4OB?=
HCT116 NYn0W2xMTnWwY4Tpc44hSXO|YYm= MnfRNlAhdk1? M{HpW|ghcA>? NHTlO2xud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= MYSyNFc{QTR3NB?=
B104  MnjsSpVv[3Srb36gRZN{[Xl? M{\GZlIhdk1? NYXDZ5c4OjRxNEivO|IhcA>? Ml3qbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi MlHzNlA3QDZ3MEW=
HL-60  M4XISGN6fG:2b4jpZ4l1gSCDc4PhfS=> NWjYc4VSOS13MECgcm0> MV:yOEBp NEfKXWJqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MWWyNFYzPDF4Mx?=
HP100 MljtR5l1d3SxeHnjbZR6KEG|c3H5 MVWxMVUxOCCwTR?= M{XQT|I1KGh? MoLXbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MlXQNlA3OjRzNkO=
HL-60  M{TzVWZ2dmO2aX;uJGF{e2G7 M1nyPFExKG6P NHq2VWU1NzZxMU[gbC=> MVPpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? MVGyNFYzPDF4Mx?=
HP100 MmLpSpVv[3Srb36gRZN{[Xl? Mlu3NVAhdk1? NXLibWFyPC94L{G2JIg> MXHpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? NHTXWm8zODZ{NEG2Ny=>
HL-60  M4nMc2Z2dmO2aX;uJGF{e2G7 M3nO[VExNTVyMDDuUS=> M1y2eVQhcA>? MUXk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? Mk\jNlA3OjRzNkO=
HP100 MojYSpVv[3Srb36gRZN{[Xl? M1rFTlExNTVyMDDuUS=> MUS0JIg> NWLGdZRV\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NV7jd5gyOjB4MkSxOlM>
11z NYDMWYtuU2mwYYPlJGF{e2G7 MoTNN{0yODBibl2= NHjPV|Nz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= MmjvNlA3ODVzNES=
SKOV-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHNRWQ1NzhxMU[gcm0> MlXQOFghcA>? MoflbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NUnHXII{OjB2MES1OlQ>
OVCAR-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:0M|gwOTZibl2= MkDLOFghcA>? M4jHPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M4G5flIxPDB2NU[0
HBL-2 NVv2R3F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnCNk0yOCCwTR?= NHzVepkzPCCq MYHJR|UxRTRwMzDuUS=> MlzPNlAxPjhyOEC=
Jeko-1 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Y[48zNTVyIH7N MV6yOEBp M2jQUWlEPTB;MUGgcm0> NUTaOWNVOjByNkiwPFA>
Granta-519 NWC4SXB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\NVlUuPDBibl2= MnPMNlQhcA>? M3n2UGlEPTB;NUiuOUBvVQ>? MmrZNlAxPjhyOEC=
L1236 M3HZXWN6fG:2b4jpZ4l1gSCDc4PhfS=> MkTENUBvVS1zMECg{txO MWS0PEBp NIfYUY9GSzVyPUCuNFch|ryP M{W2PVE6OjN|NEew
L428 M1HOeGN6fG:2b4jpZ4l1gSCDc4PhfS=> MofSNUBvVS1zMECg{txO MXe0PEBp MVrFR|UxRTBwNEOg{txO M1TGNFE6OjN|NEew
KM-H2 NYW3PGFlS3m2b4TvfIlkcXS7IFHzd4F6 MVuxJI5ONTFyMDFOwG0> NHnyZmQ1QCCq NEXKVppGSzVyPUCuOVgh|ryP NGrMXG0yQTJ|M{S3NC=>
L540Cy M{frR2N6fG:2b4jpZ4l1gSCDc4PhfS=> M17yNlEhdk1vMUCwJO69VQ>? M1S5e|Q5KGh? MmrtSWM2OD1yLkG2JO69VQ>? NHjYPIUyQTJ|M{S3NC=>
G401 MnL6SpVv[3Srb36gRZN{[Xl? M2i3c|ExKG6P NYH4V|E3OjRxNEivO|IhcA>? NGHDSppFVVOR NEC3XINqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MnXWNVkzOjF3OE[=
STM91-01 Mkf2SpVv[3Srb36gRZN{[Xl? NXTY[ppzOTBibl2= M3fPTlI1NzR6L{eyJIg> MoHkSG1UVw>? MkXjbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u Mlf5NVkzOjF3OE[=
SJSC  NV3INYxDTnWwY4Tpc44hSXO|YYm= MV:xNEBvVQ>? MkXGNlQwPDhxN{KgbC=> NH\3UItFVVOR NVzy[ph6cW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NVHRWWdGOTl{MkG1PFY>
BT16  M3PwSWZ2dmO2aX;uJGF{e2G7 Moq2NVAhdk1? M4LROVI1NzR6L{eyJIg> M{K4c2ROW09? NVXtTpNucW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NET5OmgyQTJ{MUW4Oi=>
NCI-H1299 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK2TWM2OD12LkdCtVAvOiCwZz;tcC=> NWC4bpdPOTlzN{m4PVA>
NCI-2882 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWb4RKSzVyPUGuOuKyOC5yNDDu[{9udA>? NU\ER3N3OTlzN{m4PVA>
HCC95 M3XWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhWmVKSzVyPUKuOeKyOC5yNTDu[{9udA>? NVPXd4piOTlzN{m4PVA>
NCI-H23 NGnOUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HzRmlEPTB;Mj65xtExNjJibnevcYw> MoLGNVkyPzl6OUC=
NCI-H157 NXLDUY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJTWM2OD1zLkdCtVAvODJibnevcYw> Mnm4NVkyPzl6OUC=
NCI-H460 NFH0bG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv6Vnc5UUN3ME2yMlHDuTBwMEegcocwdWx? NVTkXHFbOTlzN{m4PVA>
NCI-H1975 NEm0ZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn5SphKSzVyPUGuN:KyOC5yNDDu[{9udA>? M2fwcVE6OTd7OEmw
NCI-H820 NUnwbHV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\TTWM2OD1{LkVCtVAvOSCwZz;tcC=> NWW0PXFIOTlzN{m4PVA>
NCI-H1650 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPR4hKSzVyPUSuPeKyOC5|IH7nM41t MlrCNVkyPzl6OUC=
DTC1 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHkTWM2OD1yLkWxJI5O MlzpNVg2PjZ{NE[=
KAO NYiyN|VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\MN3lKSzVyPUCuPVEhdk1? NV73Und7OTh3Nk[yOFY>
SU-CCS-1 NXnGO3B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwOEmgcm0> M3fPdFE5PTZ4MkS2
SYO-1 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\rTWM2OD1yLk[3JI5O NUPvUGRYOTh3Nk[yOFY>
FUJI NF22[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwM{Ggcm0> MorSNVg2PjZ{NE[=
SKNMC NFHVcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwMUegcm0> MWixPFU3PjJ2Nh?=
402-91 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXqfmZKSzVyPUGuNlYhdk1? M4jVNVE5PTZ4MkS2
1765-92 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom5TWM2OD1zLke3JI5O NHzSfWMyQDV4NkK0Oi=>
JN-DSRCT-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzCTWM2OD1zLkK1JI5O NUfVdJZDOTh3Nk[yOFY>
NMS-2PC MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwOEGgcm0> MVGxPFU3PjJ2Nh?=
HL60 NWntS2FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwOE[gcm0> MlHQNVg2PjZ{NE[=
A549 NXPTdG5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jVO2lEPTB;Mz6yOEBvVQ>? NFjPUJMyQDV4NkK0Oi=>
SW480 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwNkmgcm0> MV6xPFU3PjJ2Nh?=
MCF7 NGDaT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTkdGliUUN3ME2zMlU2KG6P MXKxPFU3PjJ2Nh?=
PC-3 NIqzWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXnTWM2OD1{LkWxJI5O Mnz3NVg2PjZ{NE[=
MMRU MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;PbWlEPTB;Mj61O{BvVQ>? MYSxPFU3PjJ2Nh?=
Hs68 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3wTWM2OD1-MUCgcm0> MoDPNVg2PjZ{NE[=
hMSC-001F NYPQcolRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXUTWM2OD1-MUCgcm0> MoPTNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID